This company listing is no longer active
Amyris Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Amyris's earnings have been declining at an average annual rate of -12.4%, while the Chemicals industry saw earnings growing at 23.7% annually. Revenues have been growing at an average rate of 24% per year.
Información clave
-12.4%
Tasa de crecimiento de los beneficios
34.4%
Tasa de crecimiento del BPA
| Crecimiento de la industria Chemicals | 20.4% |
| Tasa de crecimiento de los ingresos | 24.0% |
| Rentabilidad financiera | n/a |
| Margen neto | -229.1% |
| Última actualización de beneficios | 31 Mar 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Amyris. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 23 | 268 | -615 | 484 | 0 |
| 31 Dec 22 | 270 | -529 | 495 | 0 |
| 30 Sep 22 | 259 | -341 | 455 | 0 |
| 30 Jun 22 | 236 | -213 | 400 | 0 |
| 31 Mar 22 | 223 | -89 | 328 | 0 |
| 31 Dec 21 | 342 | -270 | 259 | 0 |
| 30 Sep 21 | 357 | -417 | 200 | 0 |
| 30 Jun 21 | 343 | -467 | 168 | 0 |
| 31 Mar 21 | 321 | -585 | 144 | 0 |
| 31 Dec 20 | 173 | -382 | 137 | 0 |
| 30 Sep 20 | 134 | -351 | 143 | 0 |
| 30 Jun 20 | 135 | -325 | 138 | 0 |
| 31 Mar 20 | 167 | -293 | 137 | 0 |
| 31 Dec 19 | 153 | -270 | 134 | 0 |
| 30 Sep 19 | 128 | -240 | 119 | 0 |
| 30 Jun 19 | 108 | -258 | 112 | 0 |
| 31 Mar 19 | 60 | -202 | 101 | 0 |
| 31 Dec 18 | 64 | -223 | 91 | 0 |
| 30 Sep 18 | 112 | -287 | 84 | 0 |
| 30 Jun 18 | 122 | -253 | 73 | 0 |
| 31 Mar 18 | 133 | -250 | 69 | 0 |
| 31 Dec 17 | 128 | -202 | 64 | 0 |
| 30 Sep 17 | 85 | -139 | 57 | 0 |
| 30 Jun 17 | 87 | -116 | 53 | 0 |
| 31 Mar 17 | 71 | -119 | 48 | 0 |
| 31 Dec 16 | 67 | -97 | 48 | 0 |
| 30 Sep 16 | 55 | -94 | 48 | 0 |
| 30 Jun 16 | 37 | -151 | 51 | 0 |
| 31 Mar 16 | 35 | -185 | 54 | 0 |
| 31 Dec 15 | 34 | -222 | 56 | 0 |
| 30 Sep 15 | 36 | -118 | 57 | 4 |
| 30 Jun 15 | 44 | -78 | 57 | 4 |
| 31 Mar 15 | 45 | -66 | 56 | 4 |
| 31 Dec 14 | 43 | 2 | 55 | 0 |
| 30 Sep 14 | 47 | -195 | 56 | 0 |
| 30 Jun 14 | 38 | -183 | 55 | 0 |
| 31 Mar 14 | 39 | -186 | 56 | 0 |
| 31 Dec 13 | 41 | -235 | 57 | 4 |
| 30 Sep 13 | 32 | -139 | 60 | 0 |
| 30 Jun 13 | 44 | -135 | 64 | 0 |
| 31 Mar 13 | 52 | -143 | 72 | -2 |
| 31 Dec 12 | 74 | -205 | 79 | 0 |
| 30 Sep 12 | 109 | -221 | 85 | 6 |
Ingresos de calidad: A2MR34 is currently unprofitable.
Margen de beneficios creciente: A2MR34 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: A2MR34 is unprofitable, and losses have increased over the past 5 years at a rate of 12.4% per year.
Acelerando crecimiento: Unable to compare A2MR34's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: A2MR34 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-28.3%).
Rentabilidad financiera
Alta ROE: A2MR34's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.